MIM
ANAB icon

Monashee Investment Management’s AnaptysBio ANAB Stock Holding History

Monashee Investment Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Hold
0
– – – 17
2017
Q3 		– Sell
-25,000
Closed -$598K – 85
2017
Q2 		$598K Buy
+25,000
New +$628K 0.25% 67
2017
Q1 		– Hold
0
– – – 68

Other funds holding ANAB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Monashee Investment Management's ANAB Position: Q3 2018 in Review

Monashee Investment Management held its AnaptysBio (ANAB) position steady in Q3 2018 at 0 shares worth $6.78M. The position accounts for 1.44% of the portfolio, ranked #17.

Monashee Investment Management first reported a position in ANAB in Q2 2017 and has held it in 1 quarter since. The position peaked at $598K in Q2 2017. 129 funds tracked by Wall St. Rank hold ANAB as of Q3 2018.

  • Monashee Investment Management held 0 shares of AnaptysBio worth $6.78M as of Q3 2018.
  • Monashee Investment Management left its AnaptysBio share count unchanged in Q3 2018.
  • AnaptysBio made up 1.44% of Monashee Investment Management's portfolio in Q3 2018, its #17 holding.
  • Monashee Investment Management first reported a position in AnaptysBio in Q2 2017 and has held it in 1 quarter since.
  • Monashee Investment Management's AnaptysBio position peaked at $598K in Q2 2017.
  • 129 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2018.

Based on Monashee Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.